Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03011749
Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients
Overview
The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223 therapy and potentially be a predictive marker of hematological toxicity
Drug / Compound
dichloride
Isotope(s):
RADIUM-223
Radioisotope: Ra-223
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 11.4 Days
Decay Mode: ALPHA, BETA, GAMMA
Energy: Alpha (95%) 5-7.5 MeV Beta (3.6%) 445-492 keV Gamma (1%) 82-402 keV
Range: In Tissue <100 micrometers
Decay Daughters: 4 alpha daughters: Rn219, Po211,215, Bi211
Status: FDA Approval: XOFIGO® (2013)
Target(s):
- Bone Metabolism
Ligand Class: Small Molecules
Fluorothymidine
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- cytosolic thymidine kinase 1
Ligand Class: Small Molecules
Eligibility
Inclusion
- Metastatic castration resistant prostate cancer
- Eligible for Radium-223 therapy
Exclusion
- Inability to understand study protocol
- Extensive metastatic involvement of the axial skeleton ("superscan" on bone scintigraphy)
Share your feedback
Help us improve your experience